Influence of denaverine hydrochloride on calving ease in Holstein-Friesian heifers. Calving is assumed to be an exhausting and painful event. A drug that eases the calving procedure and alleviates pain would help cows, especially those suffering from dystocia. In a randomized, controlled, and blinded trial, we measured the effect of denaverine hydrochloride on physical and physiological calving , and cortisol concentration. The area under the curve of pulling force × time (n = 44), however, was significantly smaller in the treatment group compared with the placebo group. Also, duration of calving assistance was numerically shorter in the treatment group compared with the placebo group. The results provide evidence that calving ease can be influenced by denaverine hydrochloride during calving
Denaverine hydrochloride and carbetocin increased welfare during and after parturition and enhanced subsequent fertility in cattle. The objectives of the current study were to investigate the influence of denaverine hydrochloride and carbetocin on softening and dilatation of the birth canal, the need for assistance during parturition, calf mortality, retention of fetal membranes, endometritis , and subsequent fertility. Altogether 200 animals (100 cows and 100 heifers) of the Simmental breed were divided into 2 groups: treatment (n = 100) and control (n = 100). Animals in the treatment group received denaverine hydrochloride and carbetocin (a maximum of twice for each, depending on the progression of labor) during delivery over a maximum of 4 waiting periods (30 min each), whereas control animals
Pharmacokinetics and bioavailability of denaverine hydrochloride in healthy subjects following intravenous, oral and rectal single doses. The neurotropic-musculotropic spasmolytic agent denaverine hydrochloride is used mainly in the treatment of smooth muscle spasms of the gastrointestinal and urogenital tract. Despite its commercial availability as a solution for intravenous or intramuscular administration (ampoule) and as a suppository formulation, no pharmacokinetic data in man was available to date. Therefore, the objectives of this clinical trial were to determine the basic pharmacokinetic parameters of denaverine after intravenous administration, to assess the feasibility of using the oral route of administration and to characterise the bioavailability of the suppository formulation